|Bid||44.00 x 800|
|Ask||49.41 x 1100|
|Day's range||44.12 - 45.46|
|52-week range||39.16 - 67.79|
|Beta (3Y monthly)||3.43|
|PE ratio (TTM)||N/A|
|Earnings date||6 Mar 2019 - 11 Mar 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||75.00|
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President. Mr. Fairey will have global responsibility for oversight of all aspects of commercial operations and serve as a key member of MyoKardia’s executive leadership team. “Bill is a leader with a strong and relevant track record in building mission-driven, high-performing teams that have brought important therapies to patients with few if any options,” said Tassos Gianakakos, Chief Executive Officer of MyoKardia.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on December 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491.
MyoKardia is developing mavacamten for the chronic treatment of hypertrophic cardiomyopathy (HCM), a heritable disease caused by the presence of too many cross-bridges formed between the heart muscle proteins myosin and actin. Mavacamten is intended to normalize this excess cross-bridge formation, which underlies the hypercontractility, or elevated force of contraction, and the reduced compliance, or ability of the left ventricle to relax and fill with oxygenated blood, that are both characteristic of HCM.
MyoKardia (MYOK) delivered earnings and revenue surprises of 22.00% and 21.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 39 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry.
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of.
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy.
MyoKardia (MYOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MyoKardia (MYOK) delivered earnings and revenue surprises of 2.00% and 5.13%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?